HomeAI · summaries
Storia in 2 fonti
Ipsen to buy blood cancer company Kartos Therapeutics for $450M upfront
Ipsen will pay $450 million upfront to buy Kartos Therapeutics and its MDM2 protein-targeting drug candidate that it in-licensed from Amgen back in 2016.
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
endpoints.news
Ipsen to buy blood cancer company Kartos Therapeutics for $450M upfront
Ipsen will pay $450 million upfront to buy Kartos Therapeutics and its MDM2 protein-targeting drug candidate that it in-licensed from Amgen back in 2016.
- ·
biopharmadive.com
Ipsen’s $450M blood cancer drug; FDA selects first cohort for “pre-check” pilot program
The planned acquisition of Kartos Therapeutics would hand Ipsen a late-stage asset for myelofibrosis. Elsewhere, Sobi hit a regulatory setback and BeOne unveiled more positive…
- ·
Ipsen to scoop up Memo Therapeutics and its kidney infection drug
Ipsen buys Memo Therapeutics for €200M upfront, gaining kidney-transplant drug potravitug in its second deal this week.